US EditionAdding Neoadjuvant Nivolumab to Chemo Improved Survival in Resectable NSCLC
- The phase 3 CheckMate 816 trial, reported on June 2, 2025, demonstrated that administering nivolumab combined with chemotherapy prior to surgery enhanced long-term survival outcomes in individuals worldwide diagnosed with surgically removable non-small cell lung cancer.
- This trial addressed the high relapse risk, as more than 50% of patients with stage 2 or 3 NSCLC typically experience cancer recurrence despite surgery.
- CheckMate 816 enrolled 358 patients randomly assigned to receive either chemotherapy alone or with nivolumab, demonstrating a higher pathologic complete response rate of 24% versus 2% without increased surgical complications.
- At five years, overall survival was 65% with nivolumab plus chemotherapy versus 55% with chemotherapy alone, showing a 28% reduction in death risk , and no lung cancer deaths occurred among patients achieving pCR.
- These findings have led to the adoption of nivolumab combined with chemotherapy before surgery as the new worldwide treatment standard for suitable patients, driving ongoing studies such as NeoCOAST-2 that aim to optimize immunotherapy approaches for resectable NSCLC.
13 Articles
13 Articles
Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial)
This open-label, single-arm, phase 2 trial evaluated the efficacy and safety of neoadjuvant sintilimab combined with anlotinib and chemotherapy, followed by adjuvant sintilimab, for resectable NSCLC. Forty-five patients received anlotinib (10 mg, QD, PO, days 1–14), sintilimab (200 mg, day 1), and platinum-based chemotherapy of each three-week cycle for 3 cycles, followed by surgery within 4–6 weeks. Adjuvant sintilimab (200 mg) was administered…
Perioperative nivolumab improves outcomes in resectable NSCLC
Immunotherapy before and after surgery significantly improved EFS compared with neoadjuvant immunotherapy only for patients with resectable non-small cell lung cancer, according to a comparison of results from two randomized phase 3 trials.The benefit with perioperative immunotherapy persisted regardless of patients’ cancer stage disease stage at baseline, findings presented at
MedPage Today
Anti-Aging, Acupuncture and Health NewsAdding Neoadjuvant Nivolumab to Chemo Improved Survival in Resectable NSCLC
(MedPage Today) -- CHICAGO -- Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with chemotherapy alone for patients with resectable non-small cell lung cancer (NSCLC), the phase III CheckMate...
Medical Xpress
myscience.orgImmunotherapy before surgery improves lung cancer survival in global clinical trial
Results from a Phase III clinical trial published in the New England Journal of Medicine, show that patients with lung cancer who received an immunotherapy drug, nivolumab, along with standard chemotherapy before surgery had improved long term survival compared to those who received chemotherapy alone, at five years after completing treatment.
Addressing Critical Gaps in the Management of NSCLC and the Importance of the Next Wave of Treatment Advances
A panelist discusses how emerging research in non–small cell lung cancer (NSCLC) is focused on determining the most effective neoadjuvant/adjuvant approaches combining chemotherapy with immunotherapy, addressing tumor heterogeneity through potential combinations of targeted therapies, and investigating mechanisms of immunotherapy nonresponse to improve patient outcomes.
This is a phase 3 clinical trial whose results have just published the journal The Lancet coinciding with the presentation of the study in one of the most important citations of oncology, the Congress of the American Society of Oncology (ASCO) held in Chicago, where the latest advances in cancer research are presented. This new combination of treatment, a type of immunotherapy (atezolizumab Tecentriq®) plus the Lurbinectedin inhibitor, developed…
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
